Asset Details
Do you wish to reserve the book?
Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials
Do you wish to request the book?
Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials
2010
Overview
Purpose
Rivaroxaban is a newly developed oral medicine that direct inhibits factor Xa for the prevention and treatment of thromboembolic disorders. The objective of this study was to compare the efficacy and safety of rivaroxaban versus enoxaparin, a medicine routinely used for thromboprophylaxis after total hip or knee arthroplasty.
Methods
We performed a meta-analysis of relevant randomized controlled trials (RCTs) identified in PubMed, Cochrane library, and Embase. The primary efficacy outcome for our meta-analysis was total venous thromboembolism (VTE) and all-cause mortality. The primary safety outcome was bleeding events, which were categorized as major, clinically relevant non-major, or minor events.
Results
Eight RCTs, involving 15,586 patients, were included in our meta-analysis. Compared to enoxaparin, thromboprophylaxis with rivaroxaban was associated with significantly fewer VTE and all-cause mortality [9,244 patients, risk ratio (RR) 0.56, 95% confidence interval (CI) 0.39–0.80] cases and a similar incidence of bleeding cases (major bleeding events: 13,384 patients, RR 1.65, 95% CI 0.93-2.93; clinically relevant non-major bleeding events: 13,384 patients, RR 1.21, 95% CI 0.98–1.50; total bleeding events, 13,384 patients, RR 1.10, 95% CI 0.97–1.24). The total hip or knee arthroplasty subgroup analysis revealed consistent efficacy and safety findings.
Conclusions
Rivaroxaban was more effective than the recommended dose of enoxaparin and had a similar safety profile for thromboprophylaxis after hip and knee arthroplasty.
Publisher
Springer-Verlag,Springer,Springer Nature B.V
Subject
/ Anticoagulants - adverse effects
/ Anticoagulants - therapeutic use
/ Arthroplasty, Replacement, Hip - adverse effects
/ Arthroplasty, Replacement, Hip - mortality
/ Arthroplasty, Replacement, Knee - adverse effects
/ Arthroplasty, Replacement, Knee - mortality
/ Biological and medical sciences
/ Biomedical and Life Sciences
/ embolism
/ Enoxaparin - adverse effects
/ Enoxaparin - therapeutic use
/ Hemorrhage - chemically induced
/ Humans
/ Knee
/ Morpholines - adverse effects
/ Morpholines - therapeutic use
/ Multicenter Studies as Topic
/ Pharmacology. Drug treatments
/ Primary Prevention - methods
/ Randomized Controlled Trials as Topic
/ Thiophenes - adverse effects
/ Thiophenes - therapeutic use
/ Venous Thromboembolism - etiology
